Pharmacokinetic Evaluation Of A Proposed Adalimumab Biosimilar Msb11022 Versus The Us-Licensed Reference Product:Results Of A Randomized, Double-Blind, 3-Arm Parallel-Group, Single-Dose Trial In Healthy Subjects
MSB11022
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Pharmacokinetic Evaluation Of A Proposed Adalimumab Biosimilar Msb11022 Versus The Us-Licensed Reference Product:Results Of A Randomized, Double-Blind, 3-Arm Parallel-Group, Single-Dose Trial In Healthy Subjects ### Output: MSB11022